08 jun: Damark/vismand: Regeringen skal finde nye penge
10 jun: Overskud i APM´s containerforretning
09-06-2012 00:07:00

UPDATE: J&J to Record $600 Million Charge Due to Outstanding Lawsuits

Relateret indhold
Relateret debat
05 aug - 
Lige for en sikkerhedsskyld kan du jo tænke lidt mens d..
05 aug - 
Lige præcis, dvs. Novo har bedre forudsætninger end J&J..
05 aug - 
Fortiden er ligegyldig, fremtien er hvad betyder noget ..

--J&J to take litigation charge of about $600 million in second quarter

--Charge deals with litigation surrounding drugs Risperdal, Invega and Natrecor

--Took $1.1 billion litigation charge in the fourth quarter of 2011

(Updated to include details of previous litigation charge in the third paragraph.)

By Ben Fox Rubin

Johnson & Johnson (JNJ) said it plans to record a special charge of roughly $600 million in its second quarter to increase its accrual for potential legal settlements, as it has faced a series of lawsuits over accusations of bribery and improper drug-marketing practices.

The company said the settlement payments stem for a series of outstanding civil cases that involve its drugs Risperdal, Invega and Natrecor, as well as nursing-home pharmacy operator Omnicare Inc. (OCR).

In the fourth quarter, J&J recorded a $1.1 billion charge related to litigation settlements. At the time, Chief Financial Officer Dominic Caruso said the litigation costs were primarily linked to Risperdal. The company didn't have a similar charge in its April first-quarter report.

The health-care products company has faced lawsuits related to alleged off-label promotion of its antipsychotic treatment Risperdal, which was once J&J's top-selling drug before generic copycats hit the market, as well as legal challenges over off-label promotion of another schizophrenia treatment, Invega, and the heart-failure drug Natrecor.

Furthermore, the federal government is suing J&J, accusing it of paying kickbacks to induce Omnicare to encourage use of Risperdal and other J&J drugs.

J&J also has dealt with state lawsuits regarding its promotion of Risperdal, including an Arkansas case in which the company in April was ordered to pay $1.2 billion after a jury found that J&J's past marketing of the drug violated the state's consumer-protection laws. J&J previously was ordered to pay $327 million in a South Carolina case and $258 million in Louisiana. The company is appealing all three cases.

In January, J&J agreed to settle a Texas case for $158 million.

Meanwhile, the company agreed to pay an $85 million fine in a criminal case regarding off-label marketing of Natrecor. Parallel civil litigation still hasn't been settled.

The company in April said its first-quarter earnings rose on a foreign-exchange-related gain tied to an acquisition and lower expenses.

Shares closed Friday at $62.98 and were unchanged after hours. The stock is down 4% so far this year.

--Anjali Athavaley contributed to this report.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 08, 2012 18:07 ET (22:07 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Parken/fmd: Mesterskab og pokaltitel giver en masse i FCK

29-08-2016 16:03:52
Parken Sport & Entertainments fodboldklub, FC København, leverede fremgang i første halvår, hvor blandt andet transferaktiviteterne gav en stor hjælpende hånd, ..

Vestas/Jyske: Havmølle-joint venture bidrager positivt fra 2017

29-08-2016 14:02:43
Jyske Bank ser fortsat særdeles positivt på aktien i vindmølleproducenten Vestas, der for nylig leverede et stærkt positivt overraskende regnskab for andet kvar..

Aktier/åbning: Mærsk og Novo undviger små fald

29-08-2016 09:20:12
Mens A.P. Møller-Mærsk og medicinalsektoren holder skindet på næsen, så er de øvrige eliteaktier generelt åbnet lidt lavere efter fald i USA fredag aften. Tilta..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Godt nyt fra Nordsøen til Mærsk
2
Vestas/Jyske: Havmølle-joint venture bidrager positivt fra 2017
3
Zealand/SHB: Anbefaling løftes til "akkumuler" - NY
4
Vestas udpeger ny direktør for kommunikation og marketing
5
Mærsk/Sydbank: Melding om Sverdrup er godt nyt for Oil

Relaterede aktiekurser

Johnson & Johnson 119,92 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
30. august 2016 06:55:39
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160826.1 - EUROWEB3 - 2016-08-30 06:55:39 - 2016-08-30 06:55:39 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x